- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03707093
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
This is a Phase 1, open-label, dose-escalation, multicenter study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma. ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb. It binds to the activated human T cells via a T cell receptor CD137. T cell is a kind of lymphocyte (a subtype of white blood cells) that protects bodies by eliminating tumor cells, and normal cells infected with viruses or bacteria. By binding to CD137, the study drug is expected to enhance the activity of activated T cells and thus stimulate a more intense immune attack to kill tumor cells. ADG106 is expected to enhance the activity of activated T cells.
The primary objective of the study is to assess safety and tolerability at increasing dose levels of single agent ADG106 in subjects with advanced or metastatic solid tumors and/or non Hodgkin lymphoma Secondary Objectives
- To characterize the pharmacokinetic (PK) profiles of ADG106
- To evaluate the immunogenicity of ADG106
- To evaluate the potential anti-tumor effect of ADG106 Exploratory Objective To identify the potential biomarkers of ADG106
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Indiana
-
Lafayette, Indiana, Forente stater, 47905
- Horizon Oncology Research
-
-
Texas
-
San Antonio, Texas, Forente stater, 78229
- NEXT Oncology
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria
- Male or female, 18 years of age or older at the time of consent.
- Provide written informed consent.
- Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor and/or non-Hodgkin lymphoma who are refractory or relapsed from standard therapy and who have exhausted all available therapies.
- Life expectancy of 12 weeks or greater.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- At least one measurable lesion per RECIST 1.1 for solid tumors and per Lugano Classification for non-Hodgkin lymphoma.
- Adequate organ and bone marrow function
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days prior to study drug administration.
Exclusion Criteria
- Active central nervous system primary or secondary malignancies, active seizure disorder, spinal cord compression, or carcinomatous meningitis.
- Any active autoimmune disease or documented history of autoimmune disease.
- Infection of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV), except for the following:
- History of any non-infectious hepatitis (eg, alcohol or non-alcoholic steatohepatitis, drug-related or auto-immune hepatitis).
- History of clinically significant cardiac disease.
- Uncontrolled current illness.
8. WOCBP and sexually active fertile men with WOCBP partners who are unwilling or unable to use acceptable contraception method to avoid pregnancy.
9. Women who are pregnant at Screening or prior to study drug administration. 10. Women who are breastfeeding. 11. History of significant immune-mediated AE . 13. Systemic use of the following therapies within 28 days prior to the first dose of study drug, or longer.
14. Subjects who got either below treatment:
- Any previous anti-CD137 mAb (eg, utomilumab, urelumab) treatment.
- Subject who has received allogenic hematopoietic stem cell transplant or autologous stem cell transplanted.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: ADG106 Doseøkning
|
IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of participants experiencing dose-limiting toxicities
Tidsramme: 2 Cycles (42 days)
|
2 Cycles (42 days)
|
Number of participants experiencing clinical and laboratory adverse events (AEs)
Tidsramme: First dose to 28 days post last dose
|
First dose to 28 days post last dose
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
The area under the curve (AUC) of plasma concentration of drug
Tidsramme: From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)
|
From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)
|
Maximum concentration (Cmax)
Tidsramme: From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)
|
From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)
|
Time at which maximum concentration (Tmax)
Tidsramme: From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)
|
From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)
|
Lowest plasma concentration (C[trough])
Tidsramme: From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)
|
From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ADG106-1001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Solid Tumors, Non-Hodgkin Lymphoma
-
Istituto Clinico HumanitasFullført
-
Antengene (Hangzhou) Biologics Co., Ltd.RekrutteringAvansert solid svulst | Metastatisk solid svulst | Modent B-celle non-Hodgkin lymfomKina
-
Antengene Biologics LimitedRekrutteringAvansert solid svulst | Metastatisk solid svulst | Modent B-celle non-Hodgkin lymfomForente stater, Australia
-
Martin GutierrezHackensack Meridian Health; Karyopharm Therapeutics IncTilbaketrukket
-
Incyte CorporationAvsluttetSolid tumor malignitetForente stater, Frankrike, Storbritannia, Italia, Korea, Republikken, Japan, Spania, Israel, Danmark, Tyskland, Sveits
-
Pacylex PharmaceuticalsOzmosis Research Inc.RekrutteringAvansert solid svulst | B-celle non-hodgkin lymfomCanada
-
Cytovation ASMerck Sharp & Dohme LLCAktiv, ikke rekrutterendeAvansert solid tumor malignitetNederland, Frankrike, Spania
-
Kling Biotherapeutics B.V.RekrutteringAvansert solid tumor malignitetBelgia, Nederland
-
NewLink Genetics CorporationAvsluttetAvansert solid tumor malignitetForente stater
-
FBD Biologics LimitedRekrutteringAvansert solid svulst | Refraktært non-Hodgkin lymfomTaiwan, Forente stater
Kliniske studier på ADG106
-
Adagene (Suzhou) LimitedFullførtSolid svulst | Non-Hodgkin lymfomKina
-
Adagene IncAktiv, ikke rekrutterendeAvanserte/metastatiske solide svulsterForente stater, Australia
-
National University Hospital, SingaporeMerck Sharp & Dohme LLC; Adagene IncRekrutteringTrippel negativ brystkreft | Avansert solid svulstSingapore
-
Adagene IncRekrutteringAvanserte/metastatiske solide svulsterSingapore, Australia, Forente stater
-
Adagene (Suzhou) LimitedAvsluttetSolid svulst | Non Hodgkin lymfomKina
-
National University Hospital, SingaporeBristol-Myers Squibb; Adagene Inc; Singapore Translational Cancer ConsortiumRekrutteringMetastatisk ikke-småcellet lungekreftSingapore
-
National University Hospital, SingaporeAdagene IncRekrutteringAvansert solid svulst | HER2-negativ brystkreftSingapore